Vitamin d cream plus chemo cream may shield transplant patients from skin cancer
NCT ID NCT05699603
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study tests whether a combination of two creams—calcipotriene (a vitamin D cream) and 5-fluorouracil (a chemotherapy cream)—can prevent skin cancer in organ transplant recipients. These patients are at high risk for skin cancer, especially from precancerous spots called actinic keratosis. The trial will treat 56 kidney or lung transplant recipients with multiple actinic keratoses and measure immune cell changes in the skin to see if the treatment reduces cancer risk.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
calcipotriene plus 5-fluorouracil cream
What this could lead to
If it works, this could offer a way to lower skin cancer risk in organ transplant recipients, who are especially vulnerable.
What could go wrong
This is a small, early-phase trial (56 people) with no control group, so results may not be conclusive. The treatment may not work as well in immunosuppressed patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACTINIC KERATOSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Massachusetts General Hospital Cancer Center
Boston, Massachusetts, 02114, United States
-
Oregon Health and Science University
Portland, Oregon, 97239, United States
-
University of Arizona Cancer Center - Prevention Research Clinic
Tucson, Arizona, 85719, United States
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States